Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Buti

Showing results (241-250 of 386) with videos related to

Pageof 39
Sort By:
International Journal of Molecular Sciences|December 23, 2023
In-Host HEV Quasispecies Evolution Shows the Limits of Mutagenic Antiviral TreatmentsSergi Colomer-Castell, Josep Gregori, Damir Garcia-Cehic, et al.
World Journal of Gastroenterology|June 12, 2020
Conservation and variability of hepatitis B core at different chronic hepatitis stagesMarçal Yll, Maria Francesca Cortese, Mercedes Guerrero-Murillo, et al.
Alimentary Pharmacology & Therapeutics|August 12, 2025
Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of TreatmentGrace Lai-Hung Wong, Edward Gane, Calvin Q Pan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 14, 2006
Chronic hepatitis B: a critical appraisal of current approaches to therapyRobert P Perrillo, Robert G Gish, Marion Peters, et al.
Journal of Viral Hepatitis|May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6Eric Lawitz, Edward Gane, Jordan J Feld, et al.
Hepatology (Baltimore, Md.)|August 3, 2013
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR studyMichael W Fried, Maria Buti, Gregory J Dore, et al.
Gut|January 25, 2023
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infectionHarry L A Janssen, Jinlin Hou, Tarik Asselah, et al.
Journal of Clinical Microbiology|December 9, 2016
Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice: Comparison with Massive SequencingLeonardo Nieto-Aponte, Josep Quer, Alicia Ruiz-Ripa, et al.
The Lancet. Gastroenterology & Hepatology|April 13, 2019
Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B studyMilan J Sonneveld, Willem P Brouwer, Henry L-Y Chan, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|February 9, 2023
A pilot sentinel surveillance system to monitor treatment and treatment outcomes of chronic hepatitis B and C infections in clinical centres in three European countries, 2019Anthony Nardone, Lina Nerlander, Erika Duffell, et al.
Pageof 39

Showing results (241-250 of 386) with videos related to

Sort By:
Pageof 39
International Journal of Molecular Sciences|December 23, 2023
In-Host HEV Quasispecies Evolution Shows the Limits of Mutagenic Antiviral TreatmentsSergi Colomer-Castell, Josep Gregori, Damir Garcia-Cehic, et al.
World Journal of Gastroenterology|June 12, 2020
Conservation and variability of hepatitis B core at different chronic hepatitis stagesMarçal Yll, Maria Francesca Cortese, Mercedes Guerrero-Murillo, et al.
Alimentary Pharmacology & Therapeutics|August 12, 2025
Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of TreatmentGrace Lai-Hung Wong, Edward Gane, Calvin Q Pan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 14, 2006
Chronic hepatitis B: a critical appraisal of current approaches to therapyRobert P Perrillo, Robert G Gish, Marion Peters, et al.
Journal of Viral Hepatitis|May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6Eric Lawitz, Edward Gane, Jordan J Feld, et al.
Hepatology (Baltimore, Md.)|August 3, 2013
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR studyMichael W Fried, Maria Buti, Gregory J Dore, et al.
Gut|January 25, 2023
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infectionHarry L A Janssen, Jinlin Hou, Tarik Asselah, et al.
Journal of Clinical Microbiology|December 9, 2016
Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice: Comparison with Massive SequencingLeonardo Nieto-Aponte, Josep Quer, Alicia Ruiz-Ripa, et al.
The Lancet. Gastroenterology & Hepatology|April 13, 2019
Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B studyMilan J Sonneveld, Willem P Brouwer, Henry L-Y Chan, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|February 9, 2023
A pilot sentinel surveillance system to monitor treatment and treatment outcomes of chronic hepatitis B and C infections in clinical centres in three European countries, 2019Anthony Nardone, Lina Nerlander, Erika Duffell, et al.
Pageof 39